CoChat

Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy

Open access
Perrone, Valentina, Dovizio, Melania, Veronesi, Chiara, Citraro, Rita, De Francesco, Adele, Dell’Orco, Stefania, Di Manno, Gianluca, Paciello, Arrigo, Resta, Anna Maria, Quarta, Fabrizio, Ferrante, Nicola, Ritrovato, Daniela, Degli Esposti, Luca · 2022 · International Journal of Environmental Research and Public Health

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

This Italian retrospective study aimed to analyze the pharmaco-utilization of anti-VEGF drugs and health care costs among patients with wet age-related macular degeneration (wAMD) or other ocular diseases. A retrospective analysis was performed on administrative databases of Italian entities covering approximately six million individuals. Across January 2010–December 2017, patients aged ≥50 years with a prescription of intravitreal anti-VEGFs were included as “wAMD” patients [by wAMD hospitalization or intravitreal injections] or as “other ocular diseases” patients [by hospitalization for other ocular disorders or intravitreal injections, with concomitant diabetes diagnosis or dexamethasone treatment]. The date of first matching of inclusion criteria was index-date. wAMD-cohort. Overall, 3879 patients were included; at index-date, 82.2% were treated with Ranibizumab, 15.8% with Aflibercept, and 2% with Pegaptanib. During the follow-up, the mean/annual anti-VEGF prescription [3.6 (first-year)–0.8 (third-year)] and the total expenditure [5799.84 € (first-year)–3212.84 € (third-year)] decreased. Other ocular diseases-cohort. Overall, 2646 patients were enclosed; 85.9% were treated with Ranibizumab, 13.5% with Aflibercept, and 0.6% with Pegaptanib. During the follow-up, the mean/annual anti-VEGF prescription [3.3 (first-year)–0.5 (third-year)] and the total cost [7196.83 € (first-year)–5162.68 € (third-year)] decreased. This observational study highlighted a decline in anti-VEGF prescriptions over time in both cohorts, suggesting a trend of under-treatment that could worsen the patients’ clinical outcomes and increase health care resource consumption.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijerph19052548

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Age distribution among wAMD patients (A) and those affected by other ocular diseases (B).
Figure 1 Age distribution among wAMD patients (A) and those affected by other ocular diseases (B).CC BY · PubMed Central
Figure 2 Mean number of annual anti-VEGF prescriptions/patient during the follow-up among the wAMD-cohort.
Figure 2 Mean number of annual anti-VEGF prescriptions/patient during the follow-up among the wAMD-cohort.CC BY · PubMed Central
Figure 3 Health care-related costs during the follow-up among patients in the wAMD-cohort.
Figure 3 Health care-related costs during the follow-up among patients in the wAMD-cohort.CC BY · PubMed Central
Figure 4 Drug-related costs during the follow-up among patients of wAMD-patients stratified by age classes.
Figure 4 Drug-related costs during the follow-up among patients of wAMD-patients stratified by age classes.CC BY · PubMed Central
Figure 5 Mean number of annual anti-VEGF prescriptions/patient during the follow-up among other ocular disease-cohort patients.
Figure 5 Mean number of annual anti-VEGF prescriptions/patient during the follow-up among other ocular disease-cohort patients.CC BY · PubMed Central
Figure 6 Health care-related costs during the follow-up among patients of other ocular disease-cohorts.
Figure 6 Health care-related costs during the follow-up among patients of other ocular disease-cohorts.CC BY · PubMed Central
Figure 7 Drug-related costs during the follow-up among patients of other ocular disease patients stratified by age classes.
Figure 7 Drug-related costs during the follow-up among patients of other ocular disease patients stratified by age classes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 2

  1. Marcianò, I., Giorgianni, F., and Aliquò, I. (2017, January 25–28). Intravitreal anti-VEGF injections: Real-world data on the pattern of use using multiple administrative healthcare databases from Southern Italy. Proceedings of the 38th Congress of the Italian Pharmacological Society (SIF), Rimini, Italy.
  2. Barzey, V., Muston, D., Gerlinger, C., and Lloyd, A. (2015, January 22–24). Relationship between visual acuity and ability to perform activities in patients with diabetic macular edema. Proceedings of the 15th ESASO Retina Academy 2015, Barcelona, Spain.

Cited by

See all 8

Metadata

Authors
Perrone, V., Dovizio, M., Veronesi, C., Citraro, R., De Francesco, A., Dell’Orco, S., Di Manno, G., Paciello, A., Resta, A. M., Quarta, F., Ferrante, N., Ritrovato, D., & Degli Esposti, L.
Affiliations
  • CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, 40121 Bologna, Italy
  • Magna Graecia University (IT)
  • Unita’ Operativa di Farmacologia Clinica e Farmacovigilanza, Azienda Ospedaliero-Universitaria “Mater Domini”, Università Magna Grecia di Catanzaro, 88100 Catanzaro, Italy
  • Azienda Sanitaria Locale (ASL) Roma 6, Albano Laziale, 00100 Rome, Italy
  • Agenzia di Tutela della Salute (ATS) Bergamo, 24100 Bergamo, Italy
  • Struttura Complessa di Farmacia Territoriale Area Vasta 1, 61032 Fano, Italy
  • U.O. Epidemiologia e Statistica, Azienda Sanitaria Locale (ASL) Lecce, 73100 Lecce, Italy
  • Novartis (Italy) (IT)
Corresponding author
Perrone, Valentina
Venue
International Journal of Environmental Research and Public Health
Publisher
MDPI AG
Published
2022-02-23
Volume
19
Issue
5
Pages
2548
ISSN
1660-4601 (ISSN-L)
OpenAlex
W4214662097
Cited by
8
References
19
Citations by year
2026: 2 · 2025: 3 · 2023: 2 · 2022: 1
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novartis Farma (N/A)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
VEGF inhibitors, neovascular age-related macular degeneration, eye diseases, health care costs, intravitreal injection, ranibizumab, aflibercept, pegaptanib, prescribing trends, undertreatment, Italy
MeSH terms
Ranibizumab, Antibodies, Monoclonal, Humans, Retrospective Studies, Health Care Costs, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy. https://app.cochat.ai/papers/10.3390/ijerph19052548
The paper
Perrone, V., Dovizio, M., Veronesi, C., Citraro, R., De Francesco, A., Dell’Orco, S., Di Manno, G., Paciello, A., Resta, A. M., Quarta, F., Ferrante, N., Ritrovato, D., & Degli Esposti, L. (2022). Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph19052548

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.